It is intriguing to consider g-secretase inhibitors as antileukemia agents, with Notch signaling being a new therapeutic target, since their efficacy is predicted and there are ongoing clinical trials of g-secretase inhibitors as anti-Alzheimer drugs. However, at least two issues must be considered further.
First, according to the previous report, many Notch1-mutated T-ALL cell lines are not likely to respond to g-secretase inhibitors, although some are definitely sensitive to these agents. Indeed, we found that g-secretase inhibitors that induce apoptosis in some T-ALL cell lines did not affect many Notch1-mutated T-ALL cell lines despite the fact that these g-secretase inhibitors unambiguously blocked the activation of Notch1 (data not shown). These findings indicate that Notch1 activation is not always required for the growth of T-ALL cell lines even if they have mutations. This may be due to additional mutations during establishment of the cell line or presense of Notch-independent cell growth machinery in T-ALL cells from patients. To see whether Notch signaling is a good therapeutic target, it is important to examine fresh T-ALL cells for frequency of responsiveness to g-secretase inhibitors.
Second, with the development of g-secretase inhibitors for the treatment of Alzheimer's disease, major effort has been made to find compounds that have less effect on Notch signaling. Indeed, it has been clearly shown that the administration of large amounts of Ly411575, a compound with a strong g-secretase inhibiting activity, to mice induces severe abnormalities in the immune system and digestive tract. 8 Therefore, it is unlikely that we can divert a g-secretase inhibitor that has been developed for treatment of Alzheimer's disease to an anti-T-ALL drug. We need a careful strategy to find g-secretase inhibitors or other Notch inhibitors that could be used for T-ALL and potentially other malignancies, with acceptable side effects due to the inhibition of Notch signaling, which is required for cell life physiologically. Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative/myelodysplastic disorder of early childhood.
JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia
1 Genetic abnormalities of the three genes RAS (15-20%), neurofibromatosis type I (NF1) (25%), and protein-tyrosine phosphatase, nonreceptor type 11 (PTPN11) (34%), all of which are positioned in the GM-CSF/Ras signal transduction pathway, have been implicated in the pathogenesis of JMML. [2] [3] [4] One of these genetic abnormalities is observed in 75% of JMML patients, leaving 25% of the reported cases in which a specific mutation has yet to be detected. Recent reports described an acquired mutation of the tyrosine kinase JAK2 gene that has been found in human myeloproliferative disorders, and the single-point mutation (Val617Phe) in exon 12 was identified. [5] [6] [7] Several data demonstrate that JAK2 is physically associated with the GM-CSFRb chain, becoming activated upon challenge of myeloid cells with GM-CSF. 8 To clarify the involvement of JAK2 in the pathogenesis of JMML, we searched for mutations in the JAK2 gene in five JMML patients.
The diagnosis of JMML for each patient was confirmed according to diagnostic criteria agreed upon by the International JMML Working Group. 1 Genomic DNA was extracted from patients' bone marrow cells, and the human JAK2 exon 12 was amplified by polymerase chain reaction as described previously. 5 The resulting 460-bp amplified fragment was digested with BsaXI. The mutant allele remained undigested, whereas the wild-type allele was digested into 241, 189, and 30 bp fragments (Figure 1a) . The mutant fragment was purified and its DNA sequence was determined. The single-point mutation (Val617Phe) was detected in one patient (Figure 1b) . Here, we describe the case with the JAK2 mutation.
A 4-year-old boy was admitted to our hospital with complaints of pallor, a bleeding tendency, and abdominal distention. Physical examination revealed marked hepatosplenomegaly. Peripheral blood analysis showed severe anemia, thrombocytopenia, and hyperleukocytosis with the appearance of blasts: red blood cell count, 2.24 Â 10 12 /l; hemoglobin, 51 g/l; platelet count, 3 Â 10 9 /l; and white blood cell count, 62.7 Â 10 9 /l (neutrophils, 19%; lymphocytes, 58%; monocytes, 8%; atypical lymphocytes, 4%; metamyelocytes, 1%; myelocytes, 4%; blasts, 5%). The fetal hemoglobin level was 1.1%. Bone marrow aspiration revealed hypercellularity with 12.5% of blasts, and chromosomal analysis revealed 45 XY, À7 (20/20 cells). Spontaneous in vitro colony formation was also found. The mutation PTPN11 was not detected. The patient was diagnosed as JMML, and oral 6-MP and low-dose cytarabine were given. He received a bone marrow transplantation from his HLAidentical sibling 8 months later. He has been in complete remission for more than 3 years.
We report that the JAK2 mutation Val617Phe was found in one of five cases of JMML that were analyzed. Our results suggest that identification of the Val167Phe JAK2 mutation holds promise for new approaches, not only in myeloproliferative disorders of adults but also in JMML. Our finding warrants further investigation in a larger series of JMML patients.
Figure 1
Restriction enzyme-based assessment of the JAK2 genotype in JMML patients. (a) Exon 12 in the human JAK2 gene was amplified by PCR. The resulting 460-bp amplified fragment was digested with BsaXI. The mutant allele remained undigested (JMML3), whereas the wild-type allele was digested into fragments that were 241, 189, and 30 bp. (b) DNA sequencing was performed directly on PCR products using cycle sequencing. The fragment that was not digested by BsaXI was sequenced, revealing a G to T mutation at nucleotide 1849 of JAK2 that encoded a V617F substitution.
